| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3332014 | Hematology/Oncology Clinics of North America | 2009 | 6 Pages |
Abstract
Imatinib mesylate and perifosine are two relatively new drugs that have improved outcomes for patients with gastrointestinal stromal tumors in recent years. The ocular side effects of these two drugs are discussed in this chapter. The most common ocular side effect associated with imatinib mesylate is periorbital edema. Perifosine has been associated with a ring-shaped perilimbal corneal ulceration that can be treated with topical steroids and topical antibiotics.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
S. Serdar Dogan, Bita Esmaeli,